Radiation plus immunotherapy for metastatic kidney cancer
Part of Cancer, Injuries & trauma, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether combining radiation therapy with two types of immunotherapy (checkpoint inhibitors and an injectable drug called IMSA101) can help control metastatic kidney cancer that is only growing in a few spots. The goal is to see if this approach can shrink tumors and keep them from growing further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic clear cell kidney cancer (ccRCC) that has spread to other parts of your body.
- Your cancer is growing in no more than 5 spots (called oligoprogression) and all those spots can be treated with radiation.
- You have at least one spot of cancer that a doctor can safely inject with a study drug (IMSA101) using a needle.
- You are generally able to care for most of your daily needs (Karnofsky score of 50% or higher).
- You are 18 years or older.
- Your kidney function, liver function, and blood counts are healthy enough to participate, as checked by recent blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
This trial tests whether combining focused radiation (SBRT) with anlotinib and bimepolizumab can shrink or slow kidney cancer that has spread and cannot be surgically removed. It's designed for people with a specific type of kidney cancer who are generally healthy enough to handle these treatments.
Hear when a new OligoProgressive Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.